Why the study?
Can multimodality imaging and biomarkers detect subclinical cardiotoxicity in patients with resectable breast cancer undergoing systemic treatment?
Can multimodality imaging and biomarkers detect subclinical cardiotoxicity in patients with resectable breast cancer undergoing systemic treatment?
Multimodality imaging and biomarkers can detect subclinical cardiotoxicity in breast cancer patients before clinical symptoms appear.
Answers are grounded in this paper and cite their sources.
Multimodal assessment detects subclinical cardiotoxicity in breast cancer; hypothesis-generating and requires validation before clinical adoption.
Study of cancer patients and assessment of the cardiotoxicity risk of chemotoxic drugs has been performed using the following diagnostic methods: echocardiography with assessment of global myocardial deformation, cardiac magnetic resonance imaging, analysis of cardiac biomarkers and arterial stiffness. Application of the mentioned methods allowed to detect subclinical heart and vascular lesions before the appearance of clinical symptoms in patients resectable breast cancer and systemic treatment.
No takes yet. Share an insight, caveat, or question.
Chernyak et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: